A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 12 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 78th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 64th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 103rd largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 85 in phase 3, and was the 146th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the 104-week WA19926 core study. Eligible patients received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tocilizumab
8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
Also known as: RoActemra, Actemra
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs)
An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. AESIs included serious infections (including opportunistic infections) and abnormal liver function tests.
Time frame: Up to 112 weeks
Percentage of Adverse Events (AEs) Leading to Dose Modification and AEs Leading to Study Withdrawal
An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE.
Time frame: Up to 112 weeks
Percentage of Adverse Events With Severity as Mild, Moderate, and Severe
Time frame: Up to 112 weeks
Percent Change From Baseline in the Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Over Time
The DAS28-ESR Scale is a measure of a participant's disease activity. It is based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and erythrocyte sedimentation rate. DAS28-ESR is expressed as a score on a scale with a minimum score of 0 (low disease activity ) to a maximum score of 10 (high disease activity). A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Percent Change From Baseline in the Simplified Disease Activity Index (SDAI) Over Time
The Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC), based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter (cm) visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity. A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Change From Baseline in Tender Joint Count 66 (TJC 66) Over Time
Number of tender joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Change From Baseline in Swollen Joint Count 66 (SJC 66) Over Time
Number of swollen joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Percentage of Participants With Treatment-Free Remission According to DAS28-ESR/SDAI Remission Criteria
Treatment-free remission is remission at two consecutive assessment visits (every 12 weeks) after discontinuing study drug on the second assessment visit. Clinical remission is DAS28-ESR score \<2.6 and/or SDAI score ≤3.3. The DAS28-ESR scale is a measure of a participant's disease activity based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and ESR. DAS28-ESR scored on a scale with a minimum score of 0 (low disease activity) to a maximum score of 10 (high disease activity). The SDAI is sum of TJC and SJC, based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high (or severe) disease activity.
Time frame: Up to 104 weeks
Time to Rheumatoid Arthritis Recurrence in Participants Who Achieved Treatment-Free Remission
Time to rheumatoid arthritis (RA) recurrence = period from treatment-free remission to RA recurrence. RA recurrence was worsening of disease activity with treatment beyond supportive therapy.
Time frame: Up to 104 weeks
Percent Change in Participant's General Assessment of Disease Activity (Severity of Disease) VAS Over Time
The participant's overall assessment of their current disease activity was displayed on a 100-millimeter (mm) horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Percent Change in Participant's Assessment of Pain (VAS) Over Time
Participants' pain was assessed using a 10-mm horizontal VAS (0 to 10 mm) where 0=pain absent and 10=intolerable pain. Participants responded by placing a mark on the line to indicate their current level of pain; the distance from the left edge to the mark was recorded.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Change From Baseline in Health Assessment Questionnaire (HAQ-DI) Score Over Time
The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
| Milestone | Tocilizumab |
|---|---|
| Started | 49 |
| Completed | 43 |
| Not completed | 6 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Withdrawal of informed consent | 4 |
| Withdrew: Adverse event | 1 |
An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. AESIs included serious infections (including opportunistic infections) and abnormal liver function tests.
| percentage of participants | Tocilizumab |
|---|---|
| Adverse Events | 69.4 |
| SAEs | 10.2 |
| AESIs | 17.2 |
An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE.
| percentage of adverse events | Tocilizumab |
|---|---|
| AEs Leading to Dose Modification | 34.5 |
| AEs Leading to Study Withdrawal | 1.1 |
| percentage of adverse events | Tocilizumab |
|---|---|
| Mild | 62.1 |
| Moderate | 36.8 |
| Severe | 1.1 |
The DAS28-ESR Scale is a measure of a participant's disease activity. It is based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and erythrocyte sedimentation rate. DAS28-ESR is expressed as a score on a scale with a minimum score of 0 (low disease activity ) to a maximum score of 10 (high disease activity). A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.
| percent change | Tocilizumab |
|---|---|
| Change at Week 12 (n=42) | -35.4 ± 30.4 |
| Change at Week 24 (n=40) | -27.2 ± 35.4 |
| Change at Week 36 (n=39) | -29.3 ± 48.4 |
| Change at Week 48 (n=33) | -24.6 ± 41.0 |
| Change at Week 56 (n=34) | -32.5 ± 31.9 |
| Change at Week 68 (n=32) | -38.3 ± 25.6 |
| Change at Week 80 (n=28) | -29.4 ± 33.5 |
| Change at Week 92 (n=22) | -26.9 ± 30.9 |
| Change at Week 104 (n=26) | -38.1 ± 25.9 |
The Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC), based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter (cm) visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity. A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.
| percent change | Tocilizumab |
|---|---|
| Change at Week 12 (n=37) | -45.5 ± 33.9 |
| Change at Week 24 (n=36) | -34.7 ± 45.6 |
| Change at Week 36 (n=38) | -6.3 ± 221.1 |
| Change at Week 48 (n=36) | -12.4 ± 84.3 |
| Change at Week 56 (n=34) | -39.3 ± 66.4 |
| Change at Week 68 (n=35) | -47.3 ± 39.6 |
| Change at Week 80 (n=36) | -30.3 ± 66.9 |
| Change at Week 92 (n=36) | -12.5 ± 140.1 |
| Change at Week 104 (n=35) | -28.8 ± 115.7 |
Number of tender joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.
| tender joints | Tocilizumab |
|---|---|
| Change at Week 12 (n=49) | -5.0 ± 6.7 |
| Change at Week 24 (n=47) | -5.7 ± 9.5 |
| Change at Week 36 (n=47) | -6.6 ± 10.4 |
| Change at Week 48 (n=46) | -6.2 ± 11.8 |
| Change at Week 56 (n=44) | -6.7 ± 10.6 |
| Change at Week 68 (n=45) | -6.6 ± 10.6 |
| Change at Week 80 (n=45) | -6.2 ± 10.8 |
| Change at Week 92 (n=43) | -6.3 ± 11.9 |
| Change at Week 104 (n=43) | -7.4 ± 10.9 |
Number of swollen joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.
| swollen joints | Tocilizumab |
|---|---|
| Change at Week 12 (n=49) | -3.5 ± 7.9 |
| Change at Week 24 (n=47) | -3.7 ± 8.2 |
| Change at Week 36 (n=47) | -4.5 ± 9.9 |
| Change at Week 48 (n=46) | -4.6 ± 9.9 |
| Change at Week 56 (n=44) | -4.7 ± 9.7 |
| Change at Week 68 (n=45) | -4.9 ± 9.7 |
| Change at Week 80 (n=45) | -4.6 ± 9.7 |
| Change at Week 92 (n=43) | -4.3 ± 10.2 |
| Change at Week 104 (n=43) | -5.0 ± 10.0 |
Treatment-free remission is remission at two consecutive assessment visits (every 12 weeks) after discontinuing study drug on the second assessment visit. Clinical remission is DAS28-ESR score \<2.6 and/or SDAI score ≤3.3. The DAS28-ESR scale is a measure of a participant's disease activity based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and ESR. DAS28-ESR scored on a scale with a minimum score of 0 (low disease activity) to a maximum score of 10 (high disease activity). The SDAI is sum of TJC and SJC, based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high (or severe) disease activity.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Treatment-Free Remission According to DAS28-ESR/SDAI Remission Criteria | 71.4 |
Time to rheumatoid arthritis (RA) recurrence = period from treatment-free remission to RA recurrence. RA recurrence was worsening of disease activity with treatment beyond supportive therapy.
| weeks | Tocilizumab |
|---|---|
| Time to Rheumatoid Arthritis Recurrence in Participants Who Achieved Treatment-Free Remission | 23 (17.6 to 28.4) |
The participant's overall assessment of their current disease activity was displayed on a 100-millimeter (mm) horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.
| percent change | Tocilizumab |
|---|---|
| Change at Week 12 (n=48) | -19.6 ± 45.7 |
| Change at Week 24 (n=46) | -20.3 ± 49.8 |
| Change at Week 36 (n=46) | -17.5 ± 60.6 |
| Change at Week 48 (n=45) | 6.1 ± 92.8 |
| Change at Week 56 (n=43) | -14.2 ± 63.8 |
| Change at Week 68 (n=44) | -19.3 ± 48.6 |
| Change at Week 80 (n=44) | -9.2 ± 58.1 |
| Change at Week 92 (n=43) | -4.7 ± 67.2 |
| Change at Week 104 (n=42) | -14.2 ± 75.7 |
Participants' pain was assessed using a 10-mm horizontal VAS (0 to 10 mm) where 0=pain absent and 10=intolerable pain. Participants responded by placing a mark on the line to indicate their current level of pain; the distance from the left edge to the mark was recorded.
| percent change | Tocilizumab |
|---|---|
| Change at Week 12 (n=48) | -21.8 ± 43.2 |
| Change at Week 24 (n=46) | -20.3 ± 44.9 |
| Change at Week 36 (n=46) | -25.4 ± 50.0 |
| Change at Week 48 (n=45) | 4 ± 131.4 |
| Change at Week 56 (n=43) | -19.8 ± 66.3 |
| Change at Week 68 (n=44) | -19.9 ± 57.6 |
| Change at Week 80 (n=44) | -17.1 ± 54.2 |
| Change at Week 92 (n=43) | -10.9 ± 59.2 |
| Change at Week 104 (n=42) | -20.5 ± 61.3 |
The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
| score on a scale | Tocilizumab |
|---|---|
| Change at Week 12 (n=49) | -0.2 ± 0.4 |
| Change at Week 24 (n=46) | -0.2 ± 0.4 |
| Change at Week 36 (n=46) | -0.1 ± 0.4 |
| Change at Week 48 (n=45) | 0.0 ± 0.5 |
| Change at Week 56 (n=44) | -0.1 ± 0.6 |
| Change at Week 68 (n=45) | -0.2 ± 0.5 |
| Change at Week 80 (n=45) | -0.2 ± 0.5 |
| Change at Week 92 (n=43) | 0.0 ± 0.6 |
| Change at Week 104 (n=43) | -0.1 ± 0.5 |
Collected over Up to 112 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | 0/49 (0%) | 5/49 (10.2%) | 22/49 (44.9%) |
| Event | Tocilizumab |
|---|---|
| ArrhythmiaCardiac disorders | 1/49 |
| HypertensionVascular disorders | 1/49 |
| Cholecystitis acuteHepatobiliary disorders | 1/49 |
| Hypertensive crisisVascular disorders | 1/49 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/49 |
| Jaw abscessMusculoskeletal and connective tissue disorders | 1/49 |
| Event | Tocilizumab |
|---|---|
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 9/49 |
| Alanine aminotransferase increasedInvestigations | 5/49 |
| BronchitisInfections and infestations | 4/49 |
| Aspartate aminotransferase increasedInvestigations | 3/49 |
| DyslipidaemiaMetabolism and nutrition disorders | 3/49 |
| NeutropeniaBlood and lymphatic system disorders | 3/49 |
Full analysis set (FAS), includes all randomized participants enrolled in the study who received at least one dose of tocilizumab.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 53.3 ± 10.8 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 36 |
| Male | 13 |
The record gives a start of May 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 8 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab